A5036026491- CAR-T cell therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Nanowire Synthesis and Applications
- Biosimilars and Bioanalytical Methods
- Integrated Circuits and Semiconductor Failure Analysis
- HIV Research and Treatment
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Viral Infectious Diseases and Gene Expression in Insects
- Erythrocyte Function and Pathophysiology
- Virus-based gene therapy research
- HIV/AIDS drug development and treatment
- Peripheral Neuropathies and Disorders
- Blood groups and transfusion
- Microfluidic and Bio-sensing Technologies
- Polyomavirus and related diseases
University of Maryland, Baltimore
2021-2025
Henry M. Jackson Foundation
2021-2025
Walter Reed Army Institute of Research
2021-2025
T cells expressing chimeric antigen receptors (CARs) have shown remarkable therapeutic activity against different types of cancer. However, the wider use CAR has been hindered by potential for life-threatening toxicities due to on-target off-tumor killing low amounts target antigen. CD229, a signaling lymphocyte-activation molecule (SLAM) family member, previously identified as cell–mediated treatment multiple myeloma (MM) its high expression on surfaces MM cells. CD229 effective clearance...
ABSTRACT Lymph node T follicular helper (Tfh) cells and germinal center (GC) B are critical to generate potent antibodies but rarely possible study in humans. To understand how Tfh/GC B-cell interactions during acute HIV-1 infection (AHI) impact the generation of HIV-specific antibodies, we performed a unique cross-sectional analysis inguinal lymph biopsies taken prior antiretroviral therapy (ART) initiation AHI. Although total Tfh GC cell frequencies did not change AHI, increased...
Abstract Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are approved chimeric antigen receptor T cell (CAR T) therapies for multiple myeloma. Unfortunately, most patients receiving these treatments will experience toxicities and/or relapse highlighting the need optimizing CAR strategies. We performed first in-depth, comparative prospective biomonitoring of (N=39) cilta-cel or ide-cel in real-world setting. Cilta-cel response rates were higher, although not...
Abstract Background Aggressive B cell lymphoma with secondary central nervous system (CNS) involvement (SCNSL) carries a dismal prognosis. Chimeric antigen receptor (CAR) T cells (CAR-T) targeting CD19 have revolutionized the treatment for lymphomas; however, only single cases CNS manifestations successfully treated CAR-T been reported. Methods We prospectively enrolled 4 patients SCNSL into our study to assess clinical responses and monitor immunity. Results Two of four SNCSL responded...
Early initiation of antiretroviral therapy (ART) in acute HIV infection (AHI) is effective at limiting seeding the viral reservoir, but little known about how resultant decreased antigen load affects long-term Ab development after ART. We report here that Env-specific plasma antibody (Ab) levels and Ab-dependent cellular cytotoxicity (ADCC) increased during first 24 weeks ART correlated with persisting 48 Participants treated AHI stage 1 had lower ADCC activity on than did those later....
Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication following kidney transplantation, and there critical unmet need for PTLD treatments associated with more pronounced durable responses. To date, reports on the use of CD19-targeted chimeric antigen receptor (CAR) T (CAR-T) cells in patients after solid organ transplant (SOT) have been anecdotal, clinical presentations outcomes heterogenous, longitudinal analysis CAR-T cell expansion persistence has not...
Not available.
ABSTRACT Chimeric antigen receptor (CAR) T cells are an effective treatment for some blood cancers. However, the lack of tumor-specific surface antigens limits their wider use. We identified a set that limited in expression to cancer and central nervous system (CNS). developed CAR against one these antigens, LINGO1, which is widely expressed Ewing sarcoma (ES). To prevent CNS targeting, we engineered LINGO1 lacking integrin ⍺ 4 (A4 ko ), adhesion molecule essential migration across...
Abstract Chimeric Antigen Receptor (CAR) T cell therapy is an effective treatment for cancer patients. While CAR cells have shown remarkable efficacy, most patients receiving eventually relapse. CAR-mediated trogocytosis (CMT) a potential tumor escape mechanism involving the transfer of surface proteins from to cells. CMT results in antigen-negative and correlates with reduced persistence, possibly due increased fratricide or exhaustion. To date it has not been conclusively demonstrated that...
Chimeric antigen receptor (CAR) T cell therapy has shown remarkable efficacy in cancer treatment. Still, most patients receiving CAR cells relapse within 5 years of CAR-mediated trogocytosis (CMT) is a potential tumor escape mechanism which surface proteins transfer from to cells. CMT results the emergence antigen-negative cells, can evade future detection, and antigen-positive been suggested cause fratricide exhaustion. Whether indeed causes dysfunction molecular mechanisms conferring...
ABSTRACT T cells expressing chimeric antigen receptors have shown remarkable therapeutic activity against different types of cancer. However, their wider use has been hampered by the potential for life-threatening toxicities due to unintended targeting healthy low levels targeted antigen. We now developed an affinity-tuning approach generation minimally modified, low-affinity antibody variants derived from existing high-affinity antibodies. Using this approach, we engineered affinity fully...
Abstract Chimeric Antigen Receptor (CAR) T cells have shown remarkable anti-tumor activity in various B cell malignancies. However, expanding their use to solid tumors has proven difficult due the lack of sufficiently tumor-specific target antigens. Restricting CAR from trafficking certain healthy tissues showing shared expression an otherwise antigen may open up new avenues treatment with cells. We developed electroporation-based CRISPR/Cas9 approach targeting integrin a4 (ITGA4), a key...